论文部分内容阅读
背景资料1:西安杨森息斯敏事件 2004年3月底,在继几年前因药物不良反应被媒体 曝光之后,西安杨森的拳头产品息斯敏再度传出不良反应 报道。然而,西安杨森对这个被外界评为“比PPA事件更 严重”的事态的应对态度仅仅是:下个月起修改产品说明 书,缩小适用人群和使用范围。上海瑞金医院皮肤科一位 著名医生就此发表评论说:“不论是几年前将药品规格改
Background 1: Xi’an Yangsen’s Sismin incident At the end of March 2004, following the exposure of the drug due to adverse drug reactions several years ago, Xian Xin, the fist product of Xian Janssen, again reported adverse reactions. However, Xi’an Jansen’s response to this situation that has been rated by the outside world as ”more severe than the PPA incident" is merely to amend the product description from the next month to narrow the applicable population and scope of use. A famous doctor in Dermatology Department of Shanghai Ruijin Hospital commented on this: “No matter how many years ago the drug specifications were changed.